AI Reportedly Key to Moderna's Phase 3 Cancer Vaccine

Polymarket posted that AI reportedly helped design Moderna's personalized skin cancer vaccine after it succeeded in a Phase 3 trial. Other accounts repeated the claim and added that the companies sequence each patient's tumor, compare it to healthy DNA, and use AI to pick mutations most likely to spark an immune response. One reply noted the models are probably small neural networks. Separate posts from founders and investors shared the same headline and expressed excitement about the result.